Karnataka chief secretary P. Ravi Kumar on Wednesday said that the state government was ready to help any pharma company that will come forward to produce the Sputnik V vaccine in the state. As of now only two vaccines manufactured by the .
New Delhi:
Covaxin Phases 2 & 3 Clinical Trials for Children: Official sources said that Covaxin, the COVID-19 vaccine developed by Bharat Biotech s in collaboration with the Indian Council of Medical Research (ICMR), was on Tuesday recommended by an expert panel for phase-2 and phase-3 clinical trials on those aged between 2 and 18 years.
Sources said that the trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application, seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.
Oxford-AstraZeneca s Covishield is being manufactured by the Pune-based Serum Institute of India.
New Delhi:
Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday.
The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September.
The Hyderabad-based Bharat Biotech s indigenously developed Covaxin and Oxford-AstraZeneca s Covishield, being manufactured by the Pune-based Serum Institute of India, are currently being used in India s inoculation drive against coronavirus.
Covaxin has been developed by Hyderabad-based Bharat Biotech.
New Delhi:
Bharat Biotech s COVID-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase-2 and phase-3 clinical trials on those aged between two to 18 years, official sources said.
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur.
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) on Tuesday deliberated upon Hyderabad-based Bharat Biotech s application, seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years.